189 related articles for article (PubMed ID: 28681041)
1. Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies.
Goodman AM; Choi M; Wieduwilt M; Mulroney C; Costello C; Frampton G; Miller V; Kurzrock R
JCO Precis Oncol; 2017 Jun; 1():. PubMed ID: 28681041
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.
Galanina N; Bejar R; Choi M; Goodman A; Wieduwilt M; Mulroney C; Kim L; Yeerna H; Tamayo P; Vergilio JA; Mughal TI; Miller V; Jamieson C; Kurzrock R
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30583461
[No Abstract] [Full Text] [Related]
3. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.
Schwaederle M; Daniels GA; Piccioni DE; Fanta PT; Schwab RB; Shimabukuro KA; Parker BA; Kurzrock R
Mol Cancer Ther; 2015 Jun; 14(6):1488-94. PubMed ID: 25852059
[TBL] [Abstract][Full Text] [Related]
4. Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.
Beg S; Bareja R; Ohara K; Eng KW; Wilkes DC; Pisapia DJ; Zoughbi WA; Kudman S; Zhang W; Rao R; Manohar J; Kane T; Sigouros M; Xiang JZ; Khani F; Robinson BD; Faltas BM; Sternberg CN; Sboner A; Beltran H; Elemento O; Mosquera JM
Transl Oncol; 2021 Jan; 14(1):100944. PubMed ID: 33190043
[TBL] [Abstract][Full Text] [Related]
5. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
[TBL] [Abstract][Full Text] [Related]
6. Utility of ultrasound-guided liver tumor biopsy for next-generation sequencing-based clinical sequencing.
Eso Y; Kou T; Nagai H; Kim YH; Kanai M; Matsumoto S; Mishima M; Arasawa S; Iguchi E; Nakamura F; Takeda H; Takai A; Takahashi K; Ueda Y; Muto M; Seno H
Hepatol Res; 2019 May; 49(5):579-589. PubMed ID: 30645782
[TBL] [Abstract][Full Text] [Related]
7. The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review.
Lombardo R; Tosi F; Nocerino A; Bencardino K; Gambi V; Ricotta R; Spina F; Siena S; Sartore-Bianchi A
Front Oncol; 2020; 10():533. PubMed ID: 32457826
[No Abstract] [Full Text] [Related]
8. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
9. Analysis of
Kato S; Ross JS; Gay L; Dayyani F; Roszik J; Subbiah V; Kurzrock R
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30148248
[TBL] [Abstract][Full Text] [Related]
10. Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.
Dy GK; Nesline MK; Papanicolau-Sengos A; DePietro P; LeVea CM; Early A; Chen H; Grand'Maison A; Boland P; Ernstoff MS; Edge S; Akers S; Opyrchal M; Chatta G; Odunsi K; Pabla S; Conroy JM; Glenn ST; DeFedericis HT; Burgher B; Andreas J; Giamo V; Qin M; Wang Y; Kanehira K; Lenzo FL; Frederick P; Lele S; Galluzzi L; Kuvshinoff B; Morrison C
BMC Med Inform Decis Mak; 2019 Jan; 19(1):14. PubMed ID: 30658646
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma.
Kato S; Okamura R; Baumgartner JM; Patel H; Leichman L; Kelly K; Sicklick JK; Fanta PT; Lippman SM; Kurzrock R
Clin Cancer Res; 2018 Dec; 24(24):6248-6256. PubMed ID: 30348637
[TBL] [Abstract][Full Text] [Related]
12. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.
Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ
Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828
[TBL] [Abstract][Full Text] [Related]
14. Molecular Profiling of Advanced Malignancies: A Community Oncology Network Experience and Review of Literature.
Tayshetye P; Miller K; Monga D; Brem C; Silverman JF; Finley GG
Front Med (Lausanne); 2020; 7():314. PubMed ID: 32760731
[No Abstract] [Full Text] [Related]
15. Validity of an NGS-based multiple gene panel in identifying actionable mutations for patients with NSCLC in a Chinese hospital.
Cao W; Yan C; Wang H; Tang T; Wang H; Liu D
Oncol Lett; 2019 Jun; 17(6):5425-5434. PubMed ID: 31186761
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
17. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.
Schwaederle M; Chattopadhyay R; Kato S; Fanta PT; Banks KC; Choi IS; Piccioni DE; Ikeda S; Talasaz A; Lanman RB; Bazhenova L; Kurzrock R
Cancer Res; 2017 Oct; 77(19):5419-5427. PubMed ID: 28807936
[TBL] [Abstract][Full Text] [Related]
18. Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas.
Juan Ribelles A; Gargallo P; Berlanga P; Segura V; Yáñez Y; Juan B; Salom M; Llavador M; Font de Mora J; Castel V; Cañete A
J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33916788
[No Abstract] [Full Text] [Related]
19. Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?
von Itzstein MS; Smith ML; Railey E; White CB; Dieterich JS; Garrett-Mayer L; Bruinooge SS; Freedman AN; De Moor J; Gray SW; Park JY; Yan J; Hoang AQ; Zhu H; Gerber DE
JCO Oncol Pract; 2021 Jul; 17(7):e999-e1011. PubMed ID: 33970688
[TBL] [Abstract][Full Text] [Related]
20. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.
Groisberg R; Hong DS; Roszik J; Janku F; Tsimberidou AM; Javle M; Meric-Bernstam F; Subbiah V
Mol Cancer Ther; 2018 Jul; 17(7):1595-1601. PubMed ID: 29654067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
